At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I Study of Palbociclib Alone and in Combination in Patients With Relapsed and Refractory Leukemias
In Brief
A Phase 1 clinical trial evaluating Decitabine, Dexamethasone, and 2 other interventions for Recurrent Acute Lymphoblastic Leukemia and 3 related conditions. Active but no longer recruiting, targeting 32 participants across 1 site.
Detailed Summary
This phase I trial studies the side effects and best dose of palbociclib when given alone and in combination with sorafenib, decitabine, or dexamethasone in treating patients with leukemia that has come back (recurrent) or that does not respond to previous treatment (refractory). Palbociclib, sorafenib, and decitabine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving palbociclib alone and in combination with sorafenib, decitabine, or dexamethasone may work better in treating patients with recurrent or refractory leukemia.
Study Details
Timeline
Interventions
Given IV
Given IV or PO
Given PO
Given PO